Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells

Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma. CFZ is an epoxomicin derivative with an epoxyketone electrophilic warhead that irreversibly adducts the ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cell Proteomics
Autors principals: Federspiel, Joel D., Codreanu, Simona G., Goyal, Sandeep, Albertolle, Matthew E., Lowe, Eric, Teague, Juli, Wong, Hansen, Guengerich, F. Peter, Liebler, Daniel C.
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Biochemistry and Molecular Biology 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5054346/
https://ncbi.nlm.nih.gov/pubmed/27503896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/mcp.M116.059709
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars